^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PRPF31 (Pre-MRNA Processing Factor 31)

    i
    Other names: PRPF31, Pre-MRNA Processing Factor 31, HPrp31, PRP31, U4/U6 Small Nuclear Ribonucleoprotein Prp31, NY-BR-99, SNRNP61, Serologically Defined Breast Cancer Antigen NY-BR-99, U4/U6 SnRNP 61 KDa Protein, Protein 61K, RP11, PRP31 Pre-MRNA Processing Factor 31 Homolog (S. Cerevisiae), PRP31 Pre-MRNA Processing Factor 31 Homolog (Yeast), PRP31 Pre-MRNA Processing Factor 31 Homolog, Pre-MRNA-Processing Factor 31
    Associations

    News

    Trials
    9ms
    Platypus: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, PYC Therapeutics | Trial completion date: Mar 2025 --> Aug 2025 | Trial primary completion date: Mar 2025 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    PRPF31 (Pre-MRNA Processing Factor 31)
    11ms
    ReSa: Natural History Study of Retinitis Pigmentosa Type 11 (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Oslo University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Apr 2028 | Trial primary completion date: Jul 2023 --> Apr 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PRPF31 (Pre-MRNA Processing Factor 31)
    11ms
    Natural History of PRPF31 Mutation-Associated Retinal Dystrophy (clinicaltrials.gov)
    P=N/A, N=50, Active, not recruiting, PYC Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Feb 2026 | Trial primary completion date: Dec 2026 --> Feb 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PRPF31 (Pre-MRNA Processing Factor 31)
    12ms
    DINGO: A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001 (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, PYC Therapeutics
    New P1/2 trial
    |
    PRPF31 (Pre-MRNA Processing Factor 31)
    12ms
    Platypus: SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, PYC Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: May 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Mar 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PRPF31 (Pre-MRNA Processing Factor 31)
    1year
    Genetic Analysis of Intraductal Carcinoma of the Prostate Detected in High-Grade Prostatic Intraepithelial Neoplasia Cases. (PubMed, Cureus)
    Accurate diagnosis of IDC-P enables early intervention with precision medicine for PCa. It is useful to pay attention to HGPIN cases to avoid missing true IDC-P.
    Journal
    |
    CHEK2 (Checkpoint kinase 2) • RECQL (RecQ Like Helicase) • FANCC (FA Complementation Group C) • PRPF31 (Pre-MRNA Processing Factor 31)
    |
    CHEK2 mutation
    2years
    The splicing factor Prpf31 is required for hematopoietic stem and progenitor cell expansion during zebrafish embryogenesis. (PubMed, J Biol Chem)
    Transcriptome analysis and experimental validations revealed that Prpf31 deficiency extensively perturbed the alternative splicing of mitosis-related genes. Collectively, our findings elucidate a previously undescribed role for Prpf31 in HSPC expansion, through regulating the alternative splicing of mitosis-related genes.
    Journal
    |
    PRPF3 (Pre-MRNA Processing Factor 3) • PRPF31 (Pre-MRNA Processing Factor 31)
    2years
    Differential co-expression network analysis elucidated genes associated with sensitivity to farnesyltransferase inhibitor and prognosis of acute myeloid leukemia. (PubMed, Cancer Med)
    The prognostic indicators reported here could be considered as a resource for identifying tumorigenesis and chemoresistance to farnesyltransferase inhibitor. They could help identify important research directions for the development of new prognostic and therapeutic techniques for AML.
    Journal
    |
    GATA2 (GATA Binding Protein 2) • ETS1 (ETS Proto-Oncogene 1) • FOXP3 (Forkhead Box P3) • YBX1 (Y-Box Binding Protein 1) • PDLIM5 (PDZ And LIM Domain 5) • PRPF31 (Pre-MRNA Processing Factor 31) • KLRD1 (Killer Cell Lectin Like Receptor D1)
    almost3years
    TXNL4B regulates radioresistance by controlling the PRP3-mediated alternative splicing of FANCI. (PubMed, MedComm (2020))
    Collectively, our study highlights potential novel underlying mechanisms of the involvement of TXNL4B and alternative splicing in radioresistance. The results would benefit potential cancer radiotherapy.
    Journal
    |
    FANCI (FA Complementation Group I) • PRPF31 (Pre-MRNA Processing Factor 31)
    over3years
    Bioinformatic Data Mining for Candidate Drugs Affecting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) in Cancer Patients. (PubMed, Dis Markers)
    Aspirin, metformin, atrovastatin, thrombin, androgen and antiandrogen drugs, progesterone, Vitamin D, and Ginsengoside 20(S)-Protopanaxadiol were also documented. A bioinformatic data mining strategy identified several anticancer, immunomodulator, and other candidate drugs that may affect the risk of BRONJ in cancer patients.
    Journal
    |
    CASP8 (Caspase 8) • PPM1A (Protein Phosphatase Mg2+/Mn2+ Dependent 1A) • PPP2CA (Protein Phosphatase 2 Catalytic Subunit Alpha 2) • PRPF31 (Pre-MRNA Processing Factor 31) • TAF1 (TATA-Box Binding Protein Associated Factor 1) • UQCRB (Ubiquinol-Cytochrome C Reductase Binding Protein)
    |
    metformin • aspirin